Biomarkers of Radioresistance in Head and Neck Cancer: A New Beginning.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 39964362.
- Also identified by DOI 10.1158/1078-0432.CCR-24-4223.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The development of biomarkers of radioresistance in head and neck cancer may help personalize treatment. This commentary puts in context the findings of a secondary analysis of NRG/RTOG 9512, a trial of fractionation in T2N0 glottic cancer, which observed that NFE2L2/KEAP1/CUL3 mutations are correlated with local recurrence and disease-free survival. See related article by Guan et al., p. 1615.
Medical subject headings
- Head and Neck Neoplasms
- Biomarkers, Tumor
- Radiation Tolerance